Number To Know…1 Billion
Executive Summary
With a contribution from the Innovation Network Corporation of Japan, Konica Minolta – the Japanese conglomerate better known for its printers and copiers – agreed to pay $1bn for Ambry Genetics as the first part of planned precision medicine platform.
You may also be interested in...
Konica Minolta Adds Ambry Genetics As First Piece Of Precision Medicine Business
The $1bn deal, partly funded by the public/private Innovation Network Corporation of Japan, will create new diagnostic technologies for oncology and drug discovery, and bring a comprehensive genetic-diagnostic portfolio to Japan, among other markets.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.